This week’s MedTech tracker showcases the intersection of AI and neurotechnology, with investors backing companies advancing stroke imaging, neurotherapeutics, wearable biosensors, and neuromuscular interfaces. Capital is flowing toward U.S. expansion, regulatory milestones, and platform-scale innovation, underscoring growing confidence in data-driven neurological care. Read more below.
Brainomix extends Series C financing to $25.4M to support U.S. expansion
Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, announced a $6.5M extension to its Series C financing, in addition to the £14 million secured in March 2025, bringing the total in the round to $25.4M.
The extension round was led by existing investors, Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund, and includes participation from a new U.S.-based investor, Modi Ventures.
Co-Founder and CEO Michalis Papadakis
Last week’s tracker: ProSomnus, Flinn and more
Trinity Biotech raises $25M to advance CGM+ system
The Standby Equity Purchase Agreement with an affiliate of financing partner Yorkville Advisors Global provides the Dublin, Ireland-based company with additional funding to augment its commercialization initiatives and support its R&D programs.
Trinity said the funds can help as it progresses its product pipelines, including the CGM+ offering, a continuous glucose monitor (CGM) under development. The company unveiled the CGM+ next-gen wearable biosensor in July 2025.
President and CEO John Gillard
Pharaoh Neuro raises $20M in a Series A to advance CSF management system
The company’s oversubscribed Series A financing round was led by Arboretum Ventures, and included participation from Hatteras Venture Partners, the Laerdal Million Lives Fund, and IAG Capital Partners.
Pharaoh plans to use the funds to continue development of the system and support regulatory clearance with the US Food and Drug Administration.
CEO Amaza Reitmeier
nyra health receives €20M to expand AI neuropathy platform
AI neuro platform nyra health has raised €20M in a Series A round to expand its AI-based neurological therapy services in Europe and the US.
The company said the funding will be used to expand its technology platform in the DACH region, accelerate growth in the US and pursue its aim of setting a new standard for data-driven neurorehabilitation.
Co-Founder and CEO Moritz Schöllauf
CrannMed secures €12.5M in EIC funds for new pain relief device
CrannMed has qualified for a €12.5M accelerator grant from the European Innovation Council (EIC) to develop a chronic inflammatory pain therapy.
The company will use the first phase of the investment, worth €2.5M, to develop the technology behind its pain relief therapy. The second phase, delivering €10M, will support commercialisation of the tech within Europe and the US.
CEO Liam Farrissey
Abram Scientific secures a $11.75M Series A funding
The round was led by global pharmaceutical leader Octapharma AG, with additional participation from existing and new investors affiliated with University of Colorado Anschutz.
This funding will accelerate the development of Abram Scientific’s proprietary portable platform, CoagCare, for aiding the evaluation of blood clotting disorders.
Founder and CEO Abhishek Ramkumar
Avisi Technologies announces a $10.7M capital raise to advance novel glaucoma device development
The Series A round was led by MedVenture Partners, with participation from new investors Sherpa Healthcare Partners, SNBL-Gemseki, SBI US Gateway Fund, Golden Seeds, and OneOneFive.
This financing round had strong participation from existing investors, including Good Growth Capital, Accanto Partners, Life Sciences Greenhouse Investment, and Quaker Capital Investments.
Founder and CEO Rui Jing Jiang
Aveera Medical completes a $5.35M fundraising in regulation D offering
The offering, which had a target amount of $5.37M, was structured as a non-public equity raise, with proceeds intended to advance the company’s product development and operational goals.
The Form D indicates the offering has been closed to new investments. Regulation D filings are standard for private companies seeking capital without meeting the stringent disclosure requirements of a public offering.
CEO Joseph Steele
Eco-Inject raises £5.2M to scale reinvented autoinjector
The finance will enable Eco-Inject to scale its reinvented autoinjector and move into commercial-scale manufacturing with partners, meeting GMP regulatory standards.
The equity raise was led by British investment syndicate Adjuvo and is targeting a significant slice of a huge international market.
CEO Matthew White
Blue Arbor adds $5M in Ottobock partnership to advance neuromuscular interface
The investment positions Ottobock – also the leading shareholder in Onward an investor in Phantom Neuro – as the lead investor in Blue Arbor’s Series A financing.
The company said the investment from Ottobock builds significant momentum. It aims to move into the next phase of clinical validation, product development and commercial readiness of RESTORE.
Tod Borton CEO of Blue Arbor Technologies
Oliver Jakobi CEO of Ottobock
Pulse raises $4M in round led by 3one4 Capital
The round also saw participation from Incubate Fund Asia, Stride Ventures, and several angel investors, including the founders of logistics start-up BlackBuck and B2B agri-food processing start-up Agrizy.
The company will use the funds to accelerate product development, secure regulatory certifications and set up a new research and development (R&D) hub in Visakhapatnam, Andhra Pradesh.
Co-Founders Anshul Sharma and Nishant Goel
ATRO Medical secures €3M to advance artificial meniscus toward pivotal studies
The financing round is primarily composed of equity investments, complemented by non-dilutive funding.
It brings together MedTech investors from the Netherlands, Switzerland, and the United Arab Emirates such as 819 Capital, Thuja Capital, Bolwork International Investment and industry leaders DSM-Firmenich Ventures and Samaplast.
CEO Maarten van der Zanden
Respiree strengthens Series A syndicate to advance cardiorespiratory care
New investor, One Six 8 Ventures, joins a seasoned investor syndicate led by We Venture Capital and ClavystBio, with participation from Adaptive Capital Partners, Greenwillow Capital Management and Seeds Capital.
The Series A round supports expansion of Respiree’s commercial team and U.S. presence, including company headquarters in Houston, Texas, at the Texas Medical Center (TMC) Innovation.
Founder and CEO Gurpreet Singh
Clee Medical raises Seed funding for real-time brain imaging
The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank, Kickfund, FONGIT, and Venture Kick, alongside continued support from its partner Wyss Geneva.
The financing will support product development, clinical validation, and regulatory preparation, enabling Clee Medical to bring its Neuro Access platform closer to clinical use.
Co-Founder and CEO Matt Lapinski
